Mersana Therapeutics (MRSN) Misses Q1 EPS by 9c

Mersana Therapeutics (NASDAQ: MRSN) reported Q1 EPS of ($0.52), $0.09 worse than the analyst estimate of ($0.43). Revenue for the quarter came in at $7.8 million versus the consensus estimate of $15.4 million.

For earnings history and earnings-related data on Mersana Therapeutics (MRSN) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Benchmark Reiterates Buy Rating on Cineverse (CNVS) Ahead of Q4 Results
• Virax Biolabs announces 1-for-25 reverse stock split on Nasdaq